论文部分内容阅读
M3受体是毒蕈碱型乙酰胆碱受体的亚型之一,在人体内分布广泛。选择性M3受体拮抗剂可以竞争性地与M3受体结合,主要用于膀胱过度活动症(OAB)、慢性阻塞性肺病(COPD)和肠道易激综合症(IBS)等疾病的治疗。与非选择性拮抗剂相比,选择性M3受体拮抗剂对中枢神经以及心脏的副作用大大降低。本文对已上市及处在不同研究阶段的选择性M3受体拮抗剂进行了综述。
M3 receptor is a muscarinic acetylcholine receptor subtype, widely distributed in the human body. Selective M3 receptor antagonists competitively bind M3 receptors and are mainly used in the treatment of diseases such as overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and irritable bowel syndrome (IBS). Side effects of selective M3 receptor antagonists on the CNS and the heart are greatly reduced compared to nonselective antagonists. This review summarizes selective M3 receptor antagonists that are commercially available and are in various stages of research.